ID: ALA5271533

Max Phase: Preclinical

Molecular Formula: C10H11N5

Molecular Weight: 201.23

Associated Items:

Representations

Canonical SMILES:  Nc1ccc(-c2cnc(N)c(N)c2)cn1

Standard InChI:  InChI=1S/C10H11N5/c11-8-3-7(5-15-10(8)13)6-1-2-9(12)14-4-6/h1-5H,11H2,(H2,12,14)(H2,13,15)

Standard InChI Key:  RFBRUKJIPOHUCF-UHFFFAOYSA-N

Associated Targets(Human)

PI3-kinase p110-delta subunit 6699 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 201.23Molecular Weight (Monoisotopic): 201.1014AlogP: 0.89#Rotatable Bonds: 1
Polar Surface Area: 103.84Molecular Species: NEUTRALHBA: 5HBD: 3
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 6#RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: 6.91CX LogP: -0.11CX LogD: -0.23
Aromatic Rings: 2Heavy Atoms: 15QED Weighted: 0.64Np Likeness Score: 0.12

References

1. Yang C, Gong Y, Gao Y, Deng M, Liu X, Yang Y, Ling Y, Jia Y, Zhou Y..  (2023)  Design, synthesis and in vitro biological evaluation of 2-aminopyridine derivatives as novel PI3Kδ inhibitors for hematological cancer.,  82  [PMID:36706844] [10.1016/j.bmcl.2023.129152]

Source